Position steatment of Experts on the use of paricalcitol in CKD stage 3–4

Abstract

Chronic kidney disease mineral and bone disorders (CKD-MBD) develop in early stages of CKD. Monitoring serum levels of calcium, phosphorus PTH, alkaline phophatase activity beginning in stage 3 CKD is recommended. Hyperphosphatemia, hypocalcemia and vitamin D deficiency should be corrected. Reducing dietary phosphate intake, administering phosphate binders, calcium supplements and vitamin D naive or analogs are recommended. Paricalcitol is the only selective VDRA available in Europe. It reduces PTH levels without higher risk of hipercalcemia and hiperphosphatemia. Efficacy and safety of oral paricalcitol capsules was confirmed in several clinical and observational trials. Paricalcitol is a promising therapeutic option in 3–4 CKD stages.